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Abstract Urokinase-type plasminogen activator (u-PA) bound 
to its receptor, u-PAR, initiates signal transduction pathways 
able to induce expression of the activator protein-1 (AP-1) family 
member c-fos \\\. Since transcription factors bound to AP-1 
recognition sequences within the PAI-2 gene promoter play a role 
in basal and phorbol ester-mediated induction of PAI-2 gene 
expression, we hypothesised that u-PA/u-PAR-mediated mod-
ulation of AP-1 activity would in turn influence constitutive and 
inducible PAI-2 gene expression. Treatment of HT-1080 or U-
937 cells with high molecular weight u-PA (HMW u-PA) 
resulted in induction of nuclear proteins binding to a functional 
AP-1 element in the proximal PAI-2 promoter. This increase in 
AP-1 activity correlated with a transactivation of the PAI-2 gene 
promoter in transiently transfected HT-1080 cells. We also 
demonstrate the u-PA treatment potentiated phorbol ester 
(PMA)-mediated induction of PAI-2 mRNA, indicating that u-
PA binding produces a bone fide response in vivo. 
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1. Introduction 
Localised cell surface proteolysis forms the fundamental 
basis for cellular migration facilitating numerous biological 
and pathological processes including wound healing ([2], tis-
sue modelling), and metastatic malignant disease [3]. The plas-
minogen activation enzyme cascade is one of the major pro-
teolytic systems engaged at the cell surface. Urokinase-type 
plasminogen activator (u-PA) bound to its cell surface recep-
tor (u-PAR) concentrates cell-surface plasmin generation, and 
thus degradation of the extracellular matrix (ECM), whilst 
plasminogen activator inhibitor type-2 (PAI-2), a serine pro-
tease inhibitor, is primarily responsible for inhibition of re-
ceptor-bound u-PA activity [4]. 
In addition to its integral role in restricting plasminogen 
activation to the cell surface, occupancy of u-PAR is associ-
ated with an increase in mitogenic activity [5]. u-PAR is a 
glycosyl-phosphatidylinositol (GPI)-linked cell-surface protein 
lacking both t ransmembrane and cytoplasmic domains [6]. 
Recent studies have identified putative t ransmembrane pro-
teins and intracellular signal transduction cascades thought 
to be responsible for mediating the mitogenic effects of u-
PAR. 
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The catalytic inactivation of receptor-bound u-PA upon 
binding its natural inhibitor PAI-2 is well documented [7]. 
Modulat ion of PAI-2 gene and protein expression is a poten-
tial mechanism by which u-PA activity is controlled. Molec-
ular regulation studies have demonstrated that PAI-2 gene 
expression is maintained at low, even or undetectable levels 
in most cells but is highly induced in the presence of agents 
such as phorbol ester [8], tumour necrosis factor (TNF) [9], 
and okadaic acid [10]. Analysis of the proximal PAI-2 gene 
promoter has identified at least three functionally relevant 
regulatory sites which are responsible for constitutive and in-
ducible expression. Two of these sites are related to the AP-1 
binding site consensus sequence, while the other site is related 
to the cyclic A M P response element [11]. 
Activation of signal transduction pathways together with an 
increase in the expression of the AP-1 component c-fos [1] as a 
result of u-PAR occupancy prompted us to hypothesise that 
u-PAR activation by its ligand u-PA would increase PAI-2 
gene promoter transactivation via an AP-1-dependent mecha-
nism. Our results support this hypothesis and further suggest 
that u-PA-mediated induction of PAI-2 gene expression is 
associated with pre-existing cellular activation and that this 
effect may contribute to a potential autoregulatory phenom-
enon modulating cell-surface plasminogen activation. 
2. Materials and methods 
2.1. Cell culture and materials 
Human HT-1080 fibrosarcoma cells (American Type Culture Col-
lection, Rockville, MD) were cultured to confluence at 37°C in Nun-
clon cell culture dishes according to standard techniques in 10 ml of 
Dulbecco's modified Eagles Medium (DM EM) supplemented with 
2 mM glutamine and 10% heat-inactivated foetal calf serum (HI-
FCS, Gibco BRL, Australia). Human U-937 histiocytic lymphoma 
cells (American Tissue Culture Collection, Rockville, MD) were 
grown in suspension in Nunclon cell culture flasks at 37°C according 
to standard techniques in 30 ml of RPMI-1640 medium (Gibco BRL, 
Australia) supplemented with 2 mM glutamine and 10% HI-FCS. 
HMW-u-PA was kindly donated by ARES Serono, Australia. ATF 
was obtained from American Diagnostica (Greenwich, CT) and Phor-
bol 12-myristate 13-acetate (PMA) from Sigma (St. Louis, MO). 
Cleavage of GPI-linked proteins from the cell surface by phospho-
inositol-specific phospholipase C (PI-PLC; Sigma, St. Louis, MO) was 
performed by incubating cells with 0.75 U/ml PI-PLC for 90 min prior 
to addition of subsequent stimulatory agents. 
2.2. PAI-2 promoter deletion constructs 
PAI-2 promoter constructs, fused to the chloramphenicol acetyl 
transferase (CAT) reporter gene, used in this study included PAI-2-
1100-CAT, PAI-2-1100-CAT with either or both AP-1 sites mutated, 
and PAI-2-219-CAT. These constructs have been previously described 
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[11]. The PAI-2 AP-la site (5'-TGAATCAC-3') was substituted with 
the sequence 5'-ACCGGGT-3' whilst the PAI-2 AP-lb site (5'-
CTGAGTAA-3') was substituted with the sequence 5'-
AGAATTCT-3'. The mutant constructs were generated in the PAI-
2-CAT-1100 construct. 
2.3. Transfection studies 
Transfection of PAI-2 promoter constructs (2 |j,g) into 0.5 X 106 
HT-1080 cells was performed by the DEAE-Dextran chloroquine 
method as previously described [12]. Briefly, 0.5 X106 cells were plated 
on 60 cm2 dishes in 4 ml of supplemented DMEM and grown over-
night at 37°C. The following day, cells were transfected with 2 |ig of 
plasmid DNA containing the PAI-2 promoter fused to the CAT re-
porter gene constructs (above) in 2 ml of serum-free DMEM and 10 
Hg/ml DEAE-Dextran. Two micrograms of pRSVCAT and pBLCAT3 
[13] were also transfected in parallel and used as positive and negative 
controls, respectively. After 2 h the medium was aspirated and the 
cells subsequently incubated for 5 h in serum-supplemented DMEM 
containing 100 (iM chloroquine, aspirated, washed in PBS, subjected 
to 10% DMSO-PBS shock (2 min), rinsed twice with PBS and main-
tained overnight in fresh DMEM containing 10% serum. The follow-
ing day transfected cells were first washed in PBS and then incubated 
for 24 h in either serum-free medium or serum-free medium supple-
mented with 100 nM or 1 uM HMW-u-PA, 25 ng/ml PMA or a 
combination of HMW-u-PA and 25 ng/ml PMA. Cells were harvested 
by trypsinization, washed in PBS, centrifuged, the supernatant re-
moved and the cells finally resuspended in 100 u.1 of 0.25 M Tris-
HC1 buffer, pH 7.4, and disrupted by three cycles of freeze-thawing. 
Samples were centrifuged and cytoplasmic extracts prepared by three 
freeze-thaw cycles, collected, assessed for protein concentration of the 
cytoplasmic extracts was assessed using the BioRad dye reagent sys-
tem (BioRad, Australia). Samples were either used immediately or 
stored at -80°C. 
2.4. Chloramphenicol acetyl transferase (CAT) assay 
Cytoplasmic extracts of transfected cells (usually 50-100 |ig in 40 ju.1 
of 250 mM Tris-HCl, pH 7.4) were incubated with 5 ul of 4.4 mM 
acetyl coenzyme A (Boehringer Mannheim) and 1 lil of 
[14C]chloramphenicol (DuPont) for 4 h at 37°C. The samples were 
processed by standard techniques and subjected to analysis by thin 
layer chromatography. The percentage conversion of [14C]-
chloramphenicol to its acetylated products was quantified by phos-
phorimaging using a Fujix BAS 1000 phosphorimager. 
2.5. Preparation of nuclear proteins 
The preparation of nuclear proteins from HT-1080 or U-937 cells 
was performed using the method described by Osborn et al. [14]. 
2.6. Preparation and labelling of oligonucleotides 
Double-stranded oligonucleotides containing either the AP-1 bind-
ing consensus sequence and the AP-la binding site within the PAI-2 
gene promoter were synthesised. The oligonucleotides were gel puri-
fied by electrophoresis through a 15% polyacrylamide gel containing 
7 M urea and labelled with T4 polynucleotide kinase using standard 
techniques [12]. Annealing of complementary single stranded oligom-
ers was performed as previously described [13]. The sequences of 
oligonucleotides used for this study were: 5'-GATTCAATGACT-
CACGGCTGTG-3', (AP-1 consensus oligomer); 5'-AAAATGTT; 
GAATCACTCAAAG-3', (AP-la oligomer, complementary to the re-
gion between -110 and -90 in the PAI-2 gene promoter [11]). 
Underlined regions within the AP-1 and AP-la oligonucleotides in-
dicate the consensus AP-1 and AP-la core elements, respectively. 
The sequence of the unrelated oligomer used for the competition 
experiments was: 5'-CTGGGGCTGACAGATTTTAGCT-3'. 
2.7. ProteinlDNA binding reactions and electrophoretic mobility shift 
assay (EMSA) 
Four microlitres of HT-1080 or U-937 nuclear protein extracts con-
taining 4 ug of protein in Osborn buffer D [14] were incubated at 4°C 
for 15 min with 1 u.1 (500 ng to 1 u.g) of poly d(I-C) (Boehringer 
Mannheim, Australia) and 3 u.1 of SMK buffer (12 mM spermidine, 
1.2 mM MgCl2 and 200 mM KCL) [13]. The concentration of poly 
d(I-C) required to reduce non-specific binding was determined empiri-
cally and depended on the cell source of nuclear proteins. Four micro-
litres of 732P-labelled probe (100 cps diluted in buffer D (above)) was 
then added and the mixtures incubated on ice for a further 15 min 
before being applied to a 5% polyacrylamide gel prepared in 0.25 X T-
ris/boric acid/EDTA (TBE) buffer [12] and subjected to electrophore-
sis. The gels were dried and autoradiographed at —70°C overnight 
with an intensifying screen. For competition experiments, nuclear ex-
tracts were incubated with a 10-100-fold excess of unlabelled annealed 
oligonucleotides 15 min after addition of poly d(I-C) competitor. 
Fig. 1. Treatment of HT-1080 fibrosarcoma and U-937 histiocytic lymphoma cells with HMW u-PA increases binding activity of nuclear pro-
teins to the AP-1 consensus binding site. Nuclear proteins extracted from both HT-1080 and U-937 cells treated for 6 h with normal medium 
or medium containing 1 uM HMW-u-PA were subjected to EMSAs using a labelled oligonucleotide harbouring the AP-1 binding site. As a 
positive control for inducible AP-1 binding activity, EMSAs were also performed using nuclear extracts prepared from cells treated for 6 h 
with 25 ng/ml PMA. Competition experiments using 100 ng of unlabelled unrelated (non-self) or identical (self) oligonucleotide, indicated that 
the binding activity was specific. The position of the AP-1 shifted complex is indicated by the arrowhead at the left of each panel. The un-
bound probe (free probe) is indicated at the bottom of the figure. 
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2.8. Gel super shift procedure 
Monoclonal and polyclonal antibodies against the cAMP response 
element binding protein (CREB), the cAMP response element modu-
lator (CREM), the CREB binding protein (CBP), activator transcrip-
tion factor-2 (ATF-2), jun-D, c-jun and c-fos, specifically designed for 
supershift experiments, were obtained from Santa Cruz Inc. (USA). 
Supershifting was performed by the same procedure as the standard 
EMSA, except that 1 JJ.1 of specific antibody (1 ug total) was added to 
the nuclear extracts for 1 h before the addition of the labelled oligom-
er. Samples were then applied to a 5% native acrylamide gel, subjected 
to electrophoresis and processed as described for the EMSA proce-
dure. 
2.9. Northern blot analysis 
Isolation of total RNA from HT-1080 cells was performed by the 
method of Chomczynski and Sacchi [15]. Ten micrograms per lane of 
RNA was loaded to each lane and electrophoresed through a 1% 
agarose gel containing 20% formaldehyde before being transferred 
to Hybond-N+ membrane (Amersham, Australia). Filters were hybri-
dised overnight at 42°C in a standard 50% formamide hybridisation 
buffer [16] containing 32P-labelled cDNA inserts. The cDNAs used for 
this procedure were the EcoRl fragment of plasmid pJ7 containing 
the full-length PAI-2 cDNA [8]; the 2.5 kb Bgäl fragment of 
tPA114B [17] containing the full-length t-PA cDNA, and the full-
length cDNA for human uPAR [18]. After hybridisation, the mem-
branes were washed by standard techniques and exposed to Kodak 
BioMax film (Eastman Kodak, Rochester, NY) at —80°C with an 
intensifying screen. 
3. Results 
3.1. Treatment of U-937 and HT-1080 cells with HMW-u-PA 
increases binding of nuclear proteins to the AP-1 consensus 
sequence 
Nuclear extracts prepared from HT-1080 fibrosarcoma and 
U-937 histiocytic lymphoma cells treated for 6 h with 1 ¡J.M 
HMW u-PA were subjected to EMSA analysis using a la-
belled AP-1 consensus oligomer. Six hour stimulations were 
used as the AP-1 family of transcription factors are classed as 
immediate early genes and changes in the DNA binding ac-
tivity of these proteins, mediated by phorbol esters and other 
agents, usually occur within this time frame. 
A significant increase in binding of nuclear proteins to both 
labelled AP-1 probe oligonucleotides occurred in both HT-
1080 and U-937 cells treated with HMW-u-PA over controls 
(Fig. 1). As a positive control for induction of AP-1 binding 
activity EMSA was also performed using extracts prepared 
from 6 h PMA-treated cells [19]. Increase in AP-1 binding 
as a consequence of PMA treatment was approximately 3-
fold more effective than the induction seen with u-PA, indi-
cating that PMA is a more potent activator of the signaling 
pathways which activate and/or phosphorylate components of 
the AP-1 family of proteins (Fig. 1). Competition experiments 
confirmed that binding of nuclear proteins to the AP-1 oligo-
nucleotide from control, u-PA and PMA-treated cells was 
specific. 
3.2. Addition of HMW-u-PA to HT-1080 and U-937 cells 
increases nuclear protein binding to an oligonucleotide 
containing the AP-la binding site in the PAI-2 gene 
promoter 
Two AP-1 binding sites exist in the PAI-2 gene promoter: 
AP-la and AP-lb [13]. Mutagenesis studies have indicated 
that both sites are functionally important, although the AP-
la site has been shown to play a more prominent role in 
constitutive expression and in the response of the PAI-2 
gene to PMA in transfected HT-1080 cells [11]. To determine 
Fig. 2. Treatment of HT-1080 and U-937 cells with HMW-u-PA in-
creases binding activity of nuclear proteins which recognise the AP-
la site in the PAI-2 promoter. To determine whether HMW-u-PA 
could also increase the binding activity of nuclear proteins to the 
AP-la site in the PAI-2 gene promoter, nuclear proteins extracted 
from both HT-1080 (A) and U-937 cells (B) treated for 6 h with 
1 uM HMW-u-PA were subjected to EMSA using a labelled oligo-
nucleotide harbouring the PAI-2 AP-la binding site (see Section 2 
for the AP-la sequence). Extracts from PMA-treated cells were also 
included as a positive control. The position of the unbound oligonu-
cleotide (free probe) is indicated at the bottom of the figure. The 
position of the AP-la shifted complex is indicated by the arrowhead 
at the left of the figure. Competition experiments indicated that the 
binding activity was specific. 
whether the binding activities of nuclear proteins which rec-
ognise the functional AP-la site in the PAI-2 promoter were 
also modulated by treatment with u-PA, EMSAs were per-
formed using a labelled AP-la oligomer. Nuclear proteins 
extracted from u-PA-treated HT-1080 and U-937 cells pro-
duced a significant increase in AP-la binding activity com-
pared to untreated controls (Fig. 2A,B). This particular ex-
periment was performed on four separate occasions using 
independently prepared nuclear protein extracts: u-PA treat-
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jun) family of proteins. Results indicated specific supershifting 
with antibodies which recognised Jun D and c-jun in both 
untreated and PMA-treated cells (Fig. 3). Antibodies against 
the CREB/ATF proteins failed to produce supershifts, sug-
gesting that these particular proteins are not associating 
with the AP-la site. Despite the report of Dumler [1] of an 
increase in c-fos in ovarian carcinoma cells upon u-PA treat-
ment, we found no evidence for c-fos activity in non-treated, 
u-PA- or PMA-treated HT-1080 cells. This negative result is 
consistent with a recent report [20] which indicated that HT-
1080 cells are devoid of c-fos indicating that the distribution 
of c-fos is cell-type specific. 
Taken together, these findings suggest that the AP-la site 
binds the AP-1 members jun D and c-Jun and additional, as 
yet unidentified, nuclear proteins. 
Fig. 3. Jun D and c-jun interact with the AP-la site in the PAI-2 
gene promoter. Nuclear extracts prepared from non-treated and 
PMA-treated HT-1080 cells were used in a gel supershift experiment 
using a labelled oligonucleotide harboring the AP-la site as a probe. 
Competition experiments were performed using 100 ng of unlabelled 
AP-la or AP-1 consensus oligonucleotide in the absence of anti-
body, Specific monoclonal and polyclonal antibodies against CREB, 
CREM, CBP, ATF-2, jun-D, c-jun and c-fos included in the experi-
ment are indicated by +. 
3.4. Aminoterminal fragment of HMW-u-PA induces AP-1 
binding in U-937 cells 
To determine whether u-PA-mediated induction of AP-1 
binding was independent of the catalytic activity of u-PA, 
we assessed the effect of the aminoterminal fragment (ATF) 
of the HMW-u-PA molecule which binds efficiently to u-PAR 
but is devoid of catalytic activity [21]. EMSAs using nuclear 
extracts prepared from U-937 cells treated for 6 h with 1 uM 
ment produced a 2-3-fold increase in AP-la binding in each 
experiment. As a positive control, EMSAs were also per-
formed using nuclear extracts prepared from PMA-treated 
cells which demonstrated the expected increased in binding 
of nuclear proteins to the AP-la oligonucleotide (Fig. 
2A,B). Compared with shifts observed using the consensus 
AP-1 oligomer as a probe (Fig. 1), higher migrating complexes 
were also observed with nuclear extracts prepared from HT-
1080 cells, suggesting the presence of additional protein fac-
tors binding to the AP-la site. 
3.3. Proteins recognising the AP-la site belong to the fosljun 
family of transcription factors 
Competition experiments indicated that HT-1080 nuclear 
proteins which recognised the AP-la sequence were com-
pletely inhibited by inclusion of the unlabelled AP-la oligom-
er. Interestingly, addition of the unlabelled AP-1 consensus 
sequence did not completely compete for AP-la binding: ac-
tivity: binding activity of the slowest and fastest migrating 
protein/AP-la complexes were not competed by the consensus 
AP-1 site, suggesting that non-AP-1 proteins were generating 
these particular shifts. Cross-competition EMSA experiments 
indicated that proteins recognising the consensus AP-1 bind-
ing site were in fact completely competed by unlabelled AP-la 
oligomers, indicating that the proteins which recognise the 
AP-1 consensus site also interact with the AP-la site. 
To confirm further that the proteins which were competed 
by the consensus AP-1 oligomer were indeed members of the 
AP-1 family of proteins, supershift experiments were per-
formed using antibodies which recognise various members 
of the AP-1 family of factors (jun-D, c-jun and c-fos) as 
well as members of the CREB/ATF family (CREB, CREM, 
CBP, ATF-2). Antibodies specific for members of the CREB/ 
ATF family of proteins were included as they have been dem-
onstrated to heterodimerise with components of the AP-1 (fos/ 
Fig. 4. Treatment of U-937 cells with the ATF of u-PA increases 
AP-1 binding activity. Nuclear extracts prepared from U-937 cells 
treated for 6 h with 1 uM of the ATF of u-PA were subjected to 
EMSA using the labelled AP-1 oligomer as a probe. Results indi-
cated that ATF-treatment of cells produced an increase in AP-1 
binding activity compared with non-treated cells (lanes 1-2 com-
pared with lanes 5-6). Competition experiments (lanes 3 and 4) us-
ing 100 ng of unlabelled self and unrelated competitor, indicated 
that the AP-1 binding activity was specific. The position of the AP-
1 complex is indicated by the arrow to the left of the figure whilst 
the position of the unbound oligonucleotide (free probe) is indicated 
at the bottom of the figure. 
A.E. Dear et al.lFEBS Letters 402 (1997) 265-272 269 
Fig. 5. HMW-u-PA transactivates the PAI-2 gene promoter in transfected HT-1080 cells. HT-1080 cells were transiently transfected in duplicate 
with the wild-type -219 and wild-type -1100 bp PAI-2 promoter-CAT constructs. To assess the functional role of the AP-la and AP-lb binding 
sites in u-PA-mediated induction, cells were also transfected with a -1100 PAI-2 CAT construct containing mutations within either the AP-la 
or AP-lb binding sites. As indicated, transfected cells were stimulated for 24 h with 100 nM or 1 uM HMW-u-PA, 25 ng/ml PMA or a combi-
nation of 1 uM u-PA and 25 ng/ml PMA. CAT activities were quantitated by phosphorimaging of the TLC plates and results expressed in ar-
bitrary units. This experiment was performed in duplicate on two (AP-la mut, AP-lb mut) or three (-219, 1100 wild-type) separate occasions. 
Error bars represent SEM of samples with three data points. 
ATF demonstrated an increase in binding of nuclear proteins 
to the labelled AP-1 consensus oligonucleotide, confirming 
that the proteolytic activity of u-PA is not necessary for in-
creased binding activity of nuclear proteins to the AP-1 site 
(Fig. 4). 
3.5. HMW-u-PA transactivates the PAI-2 gene promoter in 
transfected HT-1080 cells 
To determine whether the u-PA-mediated increase in bind-
ing of nuclear proteins to the AP-la binding site would acti-
vate the PAI-2 gene promoter, HT-1080 cells were transiently 
transfected with a -219 bp PAI-2 gene promoter construct 
fused to the CAT reporter gene. The -219 PAI-2 promoter 
harbours essential regulatory elements including the two 
AP-1 binding sites (AP-la and AP-lb). Transfected cells 
were treated with HMW-u-PA (100 nM or 1 uM), 25 ng/ml 
PMA, or a combination of both agents. As shown in Fig. 5, 
stimulation of transfected cells with 100 nM or 1 (iM HMW-
u-PA alone resulted in a 2- and 4.5-fold increase in CAT 
activity, respectively, as determined by phosphorimaging anal-
ysis, while PMA-treatment resulted in a 22-fold increase in 
CAT activity. A synergistic increase in CAT activity (38-fold 
over basal levels) was observed in cells treated with a combi-
nation of 1 uM HMW-u-PA and PMA. Addition of 100 nM 
u-PA also potentiated PMA-mediated induction of CAT ac-
tivity (data not shown). Taken together, these data indicate 
that the PAI-2 gene promoter is a downstream target for 
signals initiated by u-PA bound u-PAR. 
3.6. Role of the AP-la and AP-lb binding sites in the PAI-2 
gene promoter in mediating u-PA-mediated induction of 
PAI-2 promoter activity 
A series of transient transfection experiments were per-
formed to determine whether u-PA-mediated transactivation 
of the PAI-2 promoter was dependent on either or both of the 
AP-1 binding sites in the PAI-2 gene promoter. HT-1080 cells 
were transfected with a construct harbouring the first 1100 bp 
of the PAI-2 promoter fused to the CAT reporter gene. In 
parallel, cells were transfected with the -1100 construct con-
taining mutations of either or both the AP-la or AP-lb bind-
ing sites. Transfected cells were treated for 24 h with 1 uM u-
PA, 25 ng/ml PMA, or a combination of both agents. Results 
of CAT activity assays revealed that u-PA and PMA treat-
ment alone produced a reproducible 2-fold and 14-fold in-
crease in CAT activity, respectively, in cells transfected with 
the wild-type -1100 PAI-2 CAT construct. Consistent with the 
results observed with the -219 PAI-2 construct, u-PA poten-
tiated PMA-mediated induction (28-fold over basal levels) 
(Fig. 5). Mutagenesis of the AP-la site weakened basal, u-
PA- and PMA-mediated induction of CAT activity and sig-
nificantly abrogated the potentiation by u-PA- of PMA-medi-
ated induction of CAT activity (Fig. 5). Mutagenesis of the 
AP-lb site also produced a similar effect (Fig. 5), indicating 
that this site also plays a role in mediating this effect. Muta-
genesis of both AP-1 sites in combination abolished all detect-
able basal and inducible activity (data not shown). Taken 
together, these data indicate that both the AP-la and AP-lb 
sites influence basal and PMA-mediated induction of pro-
moter activity, and are likely to be involved in conveying u-
PA- and u-PA-mediated potentiation of the PMA effect. 
Basal and inducible CAT activity generated in cells trans-
fected with the -219-PAI-2-CAT construct was significantly 
greater than observed with the -1100-PAI-2-CAT construct. 
The difference seen between these two constructs is consistent 
with previous reports of a repressor element located between 
positions -219 and -1100 [22,23]. 
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Fig. 6. HMW-u-PA potentiates PMA-mediated induction of endoge-
nous PAI-2 mRNA expression. A: Total RNA was extracted from 
HT-1080 cells untreated or treated for 24 h with 100 nM or 1 uM 
HMW-u-PA, 25 ng/ml PMA or a combination of PMA with 100 
nM or 1 uM u-PA, and subjected to Northern blotting. The filter 
was first co-hybridised with labelled cDNA probes complementary 
to PAI-2 and t-PA mRNA. The position of the 1.9 kb PAI-2 
mRNA and the 2.5 kb t-PA mRNA are indicated. The filter was 
subsequently stripped then hybridised with a labelled cDNA for the 
1.4 kb urokinase receptor (u-PAR) as indicated. B: Relative inten-
sity of the ribosomal RNA bands in each lane as assessed by ethidi-
um bromide staining of the gel. 
3.7. HMW-u-PA potentiates PMA-mediated induction of 
PAI-2 mRNA expression 
To determine whether the u-PA-mediated activation of the 
PAI-2 promoter was associated with a concomitant increase in 
endogenous PAI-2 mRNA expression, Northern blot experi-
ments were performed using RNA extracted from HT-1080 
cells treated with HMW-u-PA alone or in combination with 
PMA for a period of 24 h. Despite the previous results which 
demonstrated an increase in AP-la binding and PAI-2 pro-
moter transactivation, treatment of HT-1080 cells with u-PA 
did not produce a visible increase in PAI-2 mRNA (Fig. 6), 
possibly due to limitations in the sensitivity of the Northern 
blotting procedure. However, 1 u,M HMW-u-PA potentiated 
PMA-mediated PAI-2 mRNA at least 3-fold. Potentiation of 
u-PA-mediated induction of PAI-2 mRNA by PMA was also 
observed using 100 nM u-PA, consistent with results obtained 
from the transfection experiments. This experiment was per-
formed on three separate occasions with a near identical pat-
tern of response being observed. To determine the specificity 
of the potentiation of PAI-2 mRNA by co-treatment with 
PMA+u-PA, the filter was co-hybridised with a labelled 
cDNA fragment of the human t-PA gene. The high basal 
levels of t-PA mRNA in HT-1080 cells were unaffected by 
treatment with u-PA. PMA treatment potently suppresses t-
PA mRNA [10] and this suppressive activity was not notice-
ably affected by u-PA, although we note that the marked 
suppressive effect of t-PA by PMA would make minor effects 
of u-PA difficult to determine. However, subsequent hybrid-
isation of the stripped filter with a labelled DNA fragment 
complimentary to the human u-PAR, also indicated that basal 
and PMA-mediated inductions of u-PAR [24] were not altered 
by u-PA. Despite the presence of AP-1 sites in the u-PAR 
promoter [25]; u-PA failed to alter u-PAR expression substan-
tiating the selectivity of our effect. Although circumstantial, 
this also suggests that the AP-1-dependent mechanisms which 
operate to regulate both PAI-2 and u-PAR expression are 
likely to be different, most likely as a result of different AP-
1 components associating with the AP-1 sites in the PAI-2 and 
u-PAR gene promoters. Nonetheless, these data indicate that 
addition of u-PA to HT-1080 cells produces a selective poten-
tiation of PMA-mediated induction of endogenous PAI-2 
mRNA. 
4. Discussion 
We have demonstrated that addition of u-PA to either HT-
1080 or U-937 cells increases binding of nuclear proteins to 
both a consensus AP-1 binding site and the functional AP-la 
binding site in the PAI-2 gene promoter. u-PA-dependent AP-
la binding activity further correlated with transactivation of 
the PAI-2 gene promoter. At the level of endogenous PAI-2 
mRNA expression, u-PA treatment alone did not increase 
PAI-2 mRNA, but produced a significant and reproducible 
potentiation of PMA-mediated induction of PAI-2 mRNA. 
Results of supershift experiments identified c-jun and Jun D 
(but not jun B) as part of the assembly of factors which 
recognised the AP-la site under both basal and PMA-treated 
conditions, establishing that at least some of the proteins as-
sembling on this site were members of the AP-1 family. 
Although members of the CREB/ATF family of transcription 
factors are known to associate with members of the fos/jun 
family of proteins, we found no evidence for CREB, CREM, 
CPB or ATF-2 among the proteins binding to this site. Based 
on the results of competition experiments, it is also evident 
that additional proteins, probably not related to the AP-1 
family, also recognise this site. The identity of these proteins 
and their role in PAI-2 gene activation remains to be deter-
mined. 
To address the possibility that u-PA was indirectly inducing 
AP-1 binding by a plasmin-mediated effect, we tested whether 
the ATF of u-PA would also increase AP-1 binding. The ATF 
is devoid of catalytic activity and is known to interact with u-
PAR. Our results indicated that addition of ATF to U-937 
cells induced AP-1 binding indicating that the catalytic activ-
ity of u-PA was not required to mediate this effect. We note, 
however, that the level of induction of AP-1 binding was not 
as intense as that produced when using the complete HMW-u-
PA molecule. Recent evidence indicates that u-PA, upon bind-
ing u-PAR, cleaves domain 1 of u-PAR from domains 2 and 
3, unmasking previously cloaked u-PAR epitopes which are 
thought to enhance transmembrane signal transduction [26]. 
Since the ATF of u-PA does not possess the catalytic domain 
of u-PA, cleavage of domain 1 from domains 2 and 3 of u-
PAR cannot occur, which may explain, at least in part, this 
discrepancy. 
To further support the notion that u-PAR was indeed re-
quired for these effects, PI-PLC pretreatment of U-937 cells, 
which removes all GPI-linked proteins from the cell surface, 
resulted in complete abrogation of u-PA-mediated induction 
in AP-1 binding activity (data not shown). 
The dilemma faced by investigators of u-PAR-mediated 
signalling (as with all GPI-linked receptor-mediated signal-
ling) is reconciling how transmembrane signal transduction 
is possible given the absence of transmembrane and cytosolic 
A.E. Dear et al.lFEBS Letters 402 (1997) 265-272 271 
domains in u-PAR. So-called 'adaptor proteins' harbouring 
transmembrane and cytoplasmic domains are thought to relay 
signals initiated by u-PAR to the intracellular space. Adaptor 
molecules considered to be involved in mediating u-PAR-de-
pendent signal transduction include caveolin, a 22 kDa trans-
membrane phosphoprotein [27]. Caveolin has been detected in 
Triton X-100 insoluble complexes together with GPI-an-
chored proteins, G-proteins and non-receptor tyrosine kinases 
including c-Yes [28]. Phosphorylation of caveolin on tyrosine 
residues both in vitro and in vivo has recently been demon-
strated [29]. Stahl and Müller [30] have identified caveolin as a 
putative adaptor molecule in u-PAR-mediated signalling in 
M24met human melanoma cells. The presence of caveolin in 
transformed fibroblasts [27] is consistent with a role for this 
molecule in the signalling events associated with u-PAR-medi-
ated induction of PAI-2. In addition to caveolin, other mol-
ecules known to associate with u-PA/u-PAR complexes may 
also play a facilitatory role in mediating transmembrane sig-
nalling initiated by u-PAR. The a2-macroglobulin receptor/ 
Ldl receptor-related protein (Lrp) is capable of internalising 
u-PAR [31] and while no direct evidence has linked u-PAR-
mediated signal transduction with Lrp, this transmembrane 
protein complex could act as an 'adaptor molecule' facilitating 
u-PAR-mediated signal transduction. 
The intracellular signalling pathways responsible for u-PA-
mediated induction of PAI-2 gene expression are currently 
being investigated. Previous studies have identified the pro-
duction of second messengers in response to u-PA and ATF 
bound to the u-PAR [32], together with the association of u-
PA bound u-PAR with PKC [33], non-receptor tyrosine kin-
ases ppóOfyn, pp53/561yn and pp58/64hck and integrins in 
Triton X-100 insoluble complexes [34]. These findings suggest 
that these molecules act as intracellular mediators of u-PAR-
dependent signal transduction events. The previously de-
scribed association of u-PAR with protein kinase C (PKC), 
together with the capacity of activated PKC to initiate AP-1 
transcription factor complex binding to DNA [35] implicate 
this pathway in u-PA-mediated induction of PAI-2 gene ex-
pression. The synergistic effect of u-PA on PMA-mediated 
induction of the PAI-2 promoter suggests that signalling path-
ways in addition to PKC are recruited for this response. Sig-
nal transduction pathways, including those capable of activat-
ing the mitogen-activated protein (MAP) kinase and Jun N-
terminal kinase [36], enhance binding and transactivation po-
tential of the AP-1 transcription factor complex suggesting 
that these kinases may be involved in mediating the synergism 
seen upon costimulation of cells with PMA and u-PA. 
Our data indicates that the increased binding of transcrip-
tion factors to the AP-1 a and presumably to the AP-lb sites is 
involved in conveying uPA/uPAR-dependent induction of 
PAI-2 gene expression as mutagenesis of these sites abolished 
the u-PA-mediated increase in CAT activity. The PAI-2 pro-
moter was rendered completely non-functional when both AP-
1 sites were mutated, indicating that these sites have a role in 
controlling basal transcription. We also observed complete 
loss of the synergistic effect of u-PA on PMA-mediated in-
duction of CAT activity indicating that these sites play a 
crucial role in mediating the synergistic effect. EMSA analysis 
utilising a labelled oligonucleotide harbouring the PAI-2 AP-
lb site is currently being performed to ascertain modulation 
of transcription factor binding to this site during stimulation 
with u-PA. 
Our demonstration that u-PA treatment of HT-1080 cells, 
although producing no detectable changes in expression of 
endogenous PAI-2 mRNA, resulted in a 3-fold potentiation 
of PMA-mediated increase in PAI-2 mRNA, indicates that 
the in vitro effects of u-PA-on AP-1 a binding and PAI-2 pro-
moter transactivation produces a bone fide biological re-
sponse. 
Whether the u-PA-mediated potentiation of PMA induced 
PAI-2 mRNA levels results in an increase in either intracel-
lular, secreted or cell-associated PAI-2 protein is unknown 
and remains the subject of ongoing investigation. If so, we 
speculate that binding of PAI-2 to receptor-bound u-PA 
would promote receptor/complex internalisation [37] terminat-
ing the signal, and inhibiting downstream induction of PAI-2 
gene expression. This would establish the basis for a potential 
autoregulatory mechanism involved in modulating cell-surface 
plasminogen activation. The notion of autoregulation of com-
ponents of the plasminogen-activating system has been previ-
ously explored. Autocrine saturation of prourokinase recep-
tors has been described in human A431 cells [38] whilst 
constitutive PAI-1 biosynthesis is thought to be maintained 
by an autocrine factor in human Hep G2 hepatoma cells [39]. 
The underlying molecular mechanisms governing these obser-
vations have not been fully elucidated although documenta-
tion of u-PA/u-PAR-mediated modulation of gene expression 
including the c-fos [1], fibronectin [40] and u-PA genes [41] 
suggests that u-PAR-mediated signal transduction events 
may contribute to the autoregulatory effects previously iden-
tified. That plasminogen activators are capable of modulating 
the expression of their cognate inhibitors has been recently 
described with the identification of tissue-type plasminogen 
activator (t-PA)-mediated induction of PAI-1 antigen and 
mRNA expression [42] and establishes a precedent for our 
observations. 
In summary, our data identify induction of PAI-2 gene 
expression by its receptor bound, cognate protease u-PA, 
and molecular mechanisms responsible for this effect. The 
effect of u-PA is highly reproducible and evident at the level 
of nuclear protein-binding activity, promoter transactivation 
and potentiation of PMA-mediated induction of endogenous 
PAI-2 mRNA and suggests the presence of a potential novel 
autoregulatory mechanism involved in the regulation of cell-
surface plasminogen activation. 
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